The aryl hydrocarbon receptor is a repressor of inflammation-associated colorectal tumorigenesis in mouse

Annals of Surgery

Volumn 264, Issue 3, 2016, Pages 429-435

  Díaz Díaz, Carol J ^a   Ronnekleiv Kelly, Sean M ^a   Nukaya, Manabu ^a   Geiger, Peter G ^a   Balbo, Silvia ^b   Dator, Romel ^b   Megna, Bryant W ^a   Carney, Patrick R ^a   Bradfield, Christopher A ^c   Kennedy, Gregory D ^a,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Aryl hydrocarbon receptor; Azoxymethane; Chemoprevention; Colorectal cancer; Dextran sodium sulfate; Indole 3 carbinol; Inflammatory bowel disease

Indexed keywords

3 INDOLEMETHANOL; AROMATIC HYDROCARBON RECEPTOR; BIOLOGICAL MARKER; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; AZOXYMETHANE; DEXTRAN SULFATE; INDOLE DERIVATIVE; INDOLE-3-CARBINOL; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCENDING COLON; CANCER INCIDENCE; CANCER PREVENTION; CANCER SUSCEPTIBILITY; CHRONIC INFLAMMATION; COLITIS; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DESCENDING COLON; DNA ADDUCT; DNA DAMAGE; FEMALE; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECTUM; TUMOR LOCALIZATION; AGONISTS; ANIMAL; C57BL MOUSE; COLORECTAL NEOPLASMS; COMPLICATION; PHYSIOLOGY;

ANIMALS; AZOXYMETHANE; COLITIS; COLORECTAL NEOPLASMS; DEXTRAN SULFATE; DNA DAMAGE; GENE EXPRESSION; INDOLES; MICE; MICE, INBRED C57BL; RECEPTORS, ARYL HYDROCARBON; RNA;

EID: 84978770558     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001874     Document Type: Article

References (35)

1. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22: 191-197.
2. Adams SV, Ahnen DJ, Baron JA, et al. Survival after inflammatory bowel disease-associated colorectal cancer in the Colon Cancer Family Registry. World J Gastroenterol. 2013;19:3241-3248.
3. Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:1-20.
4. Lennard-Jones JE, Ritchie JK, Morson BC, et al. Cancer surveillance in ulcerative colitis. Experience over 15 years. Lancet. 1983;2:149-152.
5. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18(Suppl 2):1-5.
6. Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and inflammatory bowel disease; epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res. 2009;29:2727-2737.
7. Li Y, Innocentin S, Withers DR, et al. Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell. 2011;147:629-640.
8. Lee J, Cella M, McDonald K, et al. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat Immunol. 2012;13:144-151.
9. Hankinson O. The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol. 1995;35:307-340.
10. Schmidt JV, Bradfield CA. Ah receptor signaling pathways. Annu Rev Cell Dev Biol. 1996;12:55-89.
11. Nebert DW, Gonzalez FJ. P450 Genes: Structure, evolution, and regulation. Ann Rev Biochem. 1987;56:945-993.
12. Furumatsu K, Nishiumi S, Kawano Y, et al. A role of the aryl hydrocarbon receptor in attenuation of colitis. Dig Dis Sci. 2011;56:2532-2544.
13. Benson JM, Shepherd DM. Aryl hydrocarbon receptor activation by TCDD reduces inflammation associated with Crohn's disease. Toxicol Sci. 2011;120:68-78.
14. Kawajiri K, Kobayashi Y, Ohtake F, et al. Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands. Proc Natl Acad Sci U S A. 2009;106:13481-13486.
15. Robertis MD, Massi E, Poeta ML, et al. The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J Carcinog. 2011;10:9.
16. Pande K, Moran SM, Bradfield CA. Aspects of dioxin toxicity are mediated by interleukin 1-like cytokines. Mol Pharmacol. 2005;67:1393-1398.
17. Schmidt JV, Su GH, Reddy JK, et al. Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc Natl Acad Sci U S A. 1996;93:6731-6736.
18. Hong MY, Chapking RS, Wild CP, et al. Relationship between DNA adduct levels, repair enzyme, and apoptosis as a function of DNA methylation by azoxymethane. Cell Growth Differ. 1999;10:749-758.
19. Tanaka T, Kohno H, Suzuki R, et al. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci. 2003;94:965-973.
20. Perse M, Cerar A. Dextran sodium sulphate colitis mouse model: traps and tricks. J Biomed Biotechnol. 2012;2012:1-13.
21. Mattar MC, Lough D, Pishvaian MJ, et al. Current management of inflammatory bowel disease and colorectal cancer. Gastrointes Cancer Res. 2011;4:53-61.
22. Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol. 2012;18:3839-3848.
23. Saleh M, Trinchieri G. Innate immune mechanisms of colitis and colitisassociated colorectal cancer. Nat Rev Immunol. 2011;11:9-20.
24. Pott J, Hornef M. Innate immune signalling at the intestinal epithelium in homeostasis and disease. EMBO Rep. 2012;13:684-698.
25. Lahvis GP, Lindell SL, Thomas RS, et al. Portosystemic shunting and persistent fetal vascular structures in aryl hydrocarbon receptor-deficient mice. Proc Natl Acad Sci U S A. 2000;97:10442-10447.
26. Matsumoto H, Takata RH, Komeiji DY. Synthesis of the glucuronic acid conjugate of methylazoxymethanol. Cancer Res. 1979;39:3070-3073.
27. Sohn OS, Ishizaki H, Yang CS, et al. Metabolism of azoxymethane, methylazoxymethanol and Nnitrosodimethylamine by cytochrome P450IIE1. Carcinogenesis. 1991;12:127-131.
28. Fiala ES, Joseph C, Sohn OS, et al. Mechanism of benzylselenocyanate inhibition of azoxymethane-induced colon carcinogenesis in F344 rats. Cancer Res. 1991;51:2826-2830.
29. Takada H, Hirooka T, Hiramatsu Y, et al. Effect of beta-glucuronidase inhibitor on azoxymethane induced colonic carcinogenesis in rats. Cancer Res. 1982;42:331-334.
30. Tamura M, Hirakawa K, Itoh K. Comparison of colonic bacterial enzymes in gnotobiotic mice monoassociated with different intestinal bacteria. Microbial Ecol Health Dis. 1996;9:287-294.
31. Gadelle D, Raibaud P, Sacquet E. beta-Glucuronidase activities of intestinal bacteria determined both in vitro and in vivo in gnotobiotic rats. Appl Environ Microbiol. 1985;49:682-685.
32. Arimochi H, Kinouchi T, Kataoka K, et al. Effect of intestinal bacteria on formation of azoxymethane induced aberrant crypt foci in the rat colon. Biochem Biophys Res Commun. 1997;238:753-757.
33. Bjeldanes CBaL. Effect of dietary indole-3-carbinol on intestinal and hepatic monooxygenase, glutathione s-transferase and epoxide hydrolase activities in the rat. Fd Chem toxic. 1984;22 (12).
34. Gorrini C, Harris IS, Mak TW.Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12:931-947.
35. Maruthanila VL, Poornima J, Mirunalini S. Attenuation of carcinogenesis and the mechanism underlying by the influence of Indole-3-carbinol and its metabolite 3,3'-diindolylmethane: a therapeutic mavel. Adv Pharmacol Sci. 2014;2014:1-7.